



# Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3)

EudraCT Number: 2021-001050-62

EU CTIS registration number: 2022-500587-35-00

## Prescribing and Administration Guide

This guide explains how to prescribe and administer the investigational medicinal product (IMP) for participants enrolled in the TICH-3 clinical trial.

### Dispensing

Add participant name and date of randomisation to the label on the outer packaging. Do not discard the outer packaging until you have alerted the coordinating centre that a randomisation has taken place using the QR code or via <http://tich-3.ac.uk/alert> (see **Randomisation alert** below).

### Prescription

Investigational medicinal product (IMP) is prescribed on the participant's inpatient treatment chart by appropriately trained medical practitioners or health care professionals who are non-medical or independent prescribers. It is acceptable to use a handwritten or electronic prescribing system for IMP prescribing.

**Prescribe (write in participant's drug chart):** TICH-3 TRIAL Pack Number XXXXX TRANEXAMIC ACID OR PLACEBO 2 ampoules (10ml) added to 100ml Sodium Chloride Injection 0.9% administered as an IV infusion over 10 minutes.

### AND

**Prescribe (write in participant's drug chart):** TICH-3 TRIAL Pack Number XXXXX TRANEXAMIC ACID OR PLACEBO 2 ampoules (10ml) added to 250ml Sodium Chloride Injection 0.9% as an IV infusion over 8 hours.

### Administration

Administer in accordance with the prescription. The treatment can be administered by anyone qualified and appropriately trained to give intravenous injections.

### Recruitment alert:



**Please notify the coordinating centre in Nottingham as soon as possible after the treatment has been administered:**

1. Scan the QR code or enter <http://tich-3.ac.uk/alert> in your web browser which will take you to the TICH-3 website.  
*You do not need to have a TICH-3 investigator account.*
2. Enter the treatment pack ID number.
3. Enter randomisation details as prompted by the system.  
*Note: If you cannot access the website, please call the trial office on 0115 8231782 with treatment pack ID, participant's initials, date of randomisation and name of person enrolling the participant (voicemail 24/7).*
4. Enter participant details on the IMP accountability log against the allocated pack.

**Disposal of IMP packaging can take place only** after the following tasks have been completed.

- a. Participant randomisation alert completed on the TICH-3 website.
- b. Participant details added to the IMP accountability log at site.
- c. Prescription written on the participant's drug chart (using the guidance above).

### In the event of non-use:

Return any unused ampoules to clinical trials pharmacy AND record reason for non-use on the IMP accountability log.